In Silico Analysis of Alzheimer's Disease Mechanism Through DNA Methylation and Gene Expression Data

Alzheimer's Disease (AD) is a debilitating disease impairing memory and thought process with currently no cure. In the current study, GEO2R, an integrated tool in the GEO database, was used to analyze DNA methylation and gene expression datasets associated with AD. Data from the BioGRID Database were used to create a PPI network of differentially methylation and expressed AD genes (DEMEGs). Cytoscape was used to image and analyze the PPI network topologically. The DAVID bioinformatics program was utilized to do enrichment analysis in order to uncover disease associations and signaling pathways. Furthermore, small molecules were predicted using Connectivity Map 2 (Cmap 2) as potential therapeutic agents that might be exploited as pharmacological targets for the study's DEMEGs. As a result, 502 mutual DEMEGs and several hubs that may be researched further as new biomarker candidates for AD such as SMURF1 and UBE2D2 were identified. The link between AD and the MAPK signaling pathway, as well as addiction and brain diseases such as ADHD and epilepsy has been established. Additionally, candidate small molecules that can be used as therapeutics such as flucloxacillin, butamben, and acetohexamide were proposed. This study integrated DNA methylation and gene expression data to further our knowledge of the AD disease mechanism.